FCGR2A and COVID-19: Recently, Junqueira et al. and Sefik et al. reported that severe COVID-19 was closely related to SARS-CoV-2 infection of monocytes in the FcγR-dependent manner, which can cause systemic inflammation and severe COVID-19 pathogenesis,72,73 while Wang et al. showed that the fusion inhibitor EK1C4 could significantly prevent FcγR-mediated enhanced infection.74 Consequently, these pan-CoV fusion inhibitors may be particularly useful in protecting people from infection by SARS-CoV-2 Omicron sublineages and preventing the progression of inflammation-associated severe acute respiratory distress.